These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 18692064

  • 1. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation.
    Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS.
    J Mol Cell Cardiol; 2008 Dec; 45(6):742-53. PubMed ID: 18692064
    [Abstract] [Full Text] [Related]

  • 2. [Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation].
    Zhu H, Zhang W, Guo CH, Zhang G, Zhang WD, Zhong M, Yang GR, Ge ZM, Zhang Y.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 05; 85(1):45-8. PubMed ID: 15808077
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation.
    Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, Chayama K.
    J Am Coll Cardiol; 2004 Mar 03; 43(5):818-25. PubMed ID: 14998623
    [Abstract] [Full Text] [Related]

  • 4. [Changes in gelatinases expression and activity in human atria during atrial fibrillation].
    Ke D, Xu CX, Zhang JC, Chen L, Lin YZ, Lin LF, Hu XZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb 03; 33(2):137-42. PubMed ID: 15924808
    [Abstract] [Full Text] [Related]

  • 5. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.
    Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbüchel H.
    Cardiovasc Res; 2005 Sep 01; 67(4):655-66. PubMed ID: 15913581
    [Abstract] [Full Text] [Related]

  • 6. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.
    Ai Zheng; 2004 Oct 01; 23(10):1194-8. PubMed ID: 15473934
    [Abstract] [Full Text] [Related]

  • 7. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 8. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis.
    Tanney DC, Feng L, Pollock AS, Lovett DH.
    Dev Dyn; 1998 Sep 15; 213(1):121-9. PubMed ID: 9733107
    [Abstract] [Full Text] [Related]

  • 9. Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme.
    Zhang W, Zhong M, Yang GR, Li JP, Guo C, Wang Z, Zhang Y.
    Cardiovasc Pathol; 2008 Sep 15; 17(6):399-409. PubMed ID: 18706834
    [Abstract] [Full Text] [Related]

  • 10. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
    Yang K, Palm J, König J, Seeland U, Rosenkranz S, Feiden W, Rübe C, Rübe CE.
    Int J Radiat Biol; 2007 Oct 15; 83(10):665-76. PubMed ID: 17729161
    [Abstract] [Full Text] [Related]

  • 11. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation.
    Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, Knackstedt C, Schimpf T, Mischke K, Gressner A, Hanrath P, Kelm M, Schauerte P.
    J Cardiovasc Electrophysiol; 2007 Sep 15; 18(10):1076-82. PubMed ID: 17655664
    [Abstract] [Full Text] [Related]

  • 12. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R.
    J Pharmacol Exp Ther; 2006 Jan 15; 316(1):8-16. PubMed ID: 16166267
    [Abstract] [Full Text] [Related]

  • 13. Differential gene expression during atrial structural remodeling in human left and right atrial appendages in atrial fibrillation.
    Zhu H, Zhang W, Zhong M, Zhang G, Zhang Y.
    Acta Biochim Biophys Sin (Shanghai); 2011 Jul 15; 43(7):535-41. PubMed ID: 21659381
    [Abstract] [Full Text] [Related]

  • 14. Gelatinases and their tissue inhibitors during human ovulation: increased expression of tissue inhibitor of matrix metalloproteinase-1.
    Lind AK, Dahm-Kähler P, Weijdegård B, Sundfeldt And K, Brännström M.
    Mol Hum Reprod; 2006 Dec 15; 12(12):725-36. PubMed ID: 17071711
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases by cytokines and growth factors in bovine endometrial stromal cells and trophoblast cell line BT-1 in vitro.
    Hirata M, Sato T, Tsumagari M, Shimada A, Nakano H, Hashizume K, Ito A.
    Biol Reprod; 2003 Apr 15; 68(4):1276-81. PubMed ID: 12606436
    [Abstract] [Full Text] [Related]

  • 16. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells.
    Eichler W, Friedrichs U, Thies A, Tratz C, Wiedemann P.
    Invest Ophthalmol Vis Sci; 2002 Aug 15; 43(8):2767-73. PubMed ID: 12147614
    [Abstract] [Full Text] [Related]

  • 17. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation.
    Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L.
    Circulation; 2004 Jan 27; 109(3):363-8. PubMed ID: 14732752
    [Abstract] [Full Text] [Related]

  • 18. Alterations in matrix metalloproteinase-9 levels and tissue inhibitor of matrix metalloproteinases-1 expression in a transforming growth factor-beta transgenic model of hydrocephalus.
    Zechel J, Gohil H, Lust WD, Cohen A.
    J Neurosci Res; 2002 Sep 01; 69(5):662-8. PubMed ID: 12210832
    [Abstract] [Full Text] [Related]

  • 19. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells.
    Ito I, Fixman ED, Asai K, Yoshida M, Gounni AS, Martin JG, Hamid Q.
    Clin Exp Allergy; 2009 Sep 01; 39(9):1370-80. PubMed ID: 19522858
    [Abstract] [Full Text] [Related]

  • 20. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
    Bai SX, Wang YL, Qin L, Xiao ZJ, Herva R, Piao YS.
    Reproduction; 2005 Jan 01; 129(1):103-13. PubMed ID: 15615902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.